3-[(3-{[3-(4,5-dihydro-1H-imidazol-2-ylamino)benzoyl]amino}phenyl)sulfinyl]-3-phenylpropanoic acid | 372986-63-5

• 分子结构分类: 有机化合物
• 英文名称: 3-[(3-{[3-(4,5-dihydro-1H-imidazol-2-ylamino)benzoyl]amino}phenyl)sulfinyl]-3-phenylpropanoic acid
• 英文别名: 3-[3-[[3-(4,5-dihydro-1H-imidazol-2-ylamino)benzoyl]amino]phenyl]sulfinyl-3-phenylpropanoic acid
• CAS: 372986-63-5
• 化学式: C₂₅H₂₄N₄O₄S
• 分子量: 476.556
• InChiKey: REHTWZKCAWFMCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  139
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Propanoic acid derivatives as intergrin receptor antagonists
  申请人：——

  公开号：US20030144311A1

  公开（公告）日：2003-07-31

  Novel propanoic acid derivatives are integrin receptor antagonists or inhibitors, in particular of the avb3 integrin receptor. The compounds of the invention are for instance useful for the treatment of solid tumors by inhibition of angiogenic growth of tumor vessel network, thus promoting tumor regression, inhibition of metastatic spread, thus avoiding cancer metastases, inhibition of bone resorption, thus controlling osteoporosis, inhibition of smooth muscle cells migration into neointima, thus blocking restenosis after percutaneous coronary angioplasty and the treatment of other pathological conditions mediated by cell adhesion, cell migration or angiogenesis such e.g. diabetic retinopaty, rheumatoid arthritis and inflammation.

  新型丙酸衍生物是整合素受体拮抗剂或抑制剂，尤其是avb3整合素受体的拮抗剂或抑制剂。本发明的化合物可用于治疗实体瘤，例如抑制肿瘤血管网络的血管生成生长，从而促进肿瘤消退；抑制转移扩散，从而避免癌症转移；抑制骨吸收，从而控制骨质疏松症；抑制平滑肌细胞向新生血管内膜迁移，从而阻断经皮冠状动脉血管成形术后的再狭窄；以及治疗由细胞粘附、细胞迁移或血管生成介导的其他病理状况，例如糖尿病视网膜病变、类风湿性关节炎等。糖尿病视网膜病变、类风湿性关节炎和炎症等。
• PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1282602B1

  公开（公告）日：2005-09-21
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES
  申请人：Reiser Jochen

  公开号：US20100297139A1

  公开（公告）日：2010-11-25

  The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.
• Methods and Compositions for the Treatment of Proteinuric Diseases
  申请人：The General Hospital Corporation

  公开号：US20160296592A1

  公开（公告）日：2016-10-13

  The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.
• US6974828B2
  申请人：——

  公开号：US6974828B2

  公开（公告）日：2005-12-13